Erratum To: Successes and Failures: What Did We Learn From Recent First-Line Treatment Immunotherapy Trials in Non-Small Cell Lung Cancer?

BMC Medicine - United Kingdom
doi 10.1186/s12916-017-0857-x
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

What Can We Learn Regarding Immunotherapy From Lung Cancer

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Immunotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Latest Immunotherapy Methods in Non-Small Cell Lung Cancer Treatment

Juntendo Medical Journal
2019English

What Did We Learn From PET/MR?

Journal of Nuclear Cardiology
Nuclear MedicineRadiologyCardiovascular MedicineImagingCardiology
2019English

Immunotherapy for Non-Small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome: Erratum

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

What Phase III Trials Are Needed to Improve the Treatment of Advanced Non-Small-Cell Lung Cancer?

Nature Clinical Practice Oncology
2005English

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy